Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines

This publication has 24 references indexed in Scilit:

• Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
  Journal of Clinical Oncology, 2002
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma
  Journal of Clinical Oncology, 1999
• erbB-2 and Response to Doxorubicin in Patients With Axillary Lymph Node-Positive, Hormone Receptor- Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 1998
• ERBB2 oncogene in human breast cancer and its clinical significance
  European Journal Of Cancer, 1998
• Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain
  Oncology, 1996
• HER-2/neu expression: A major prognostic factor in endometrial cancer
  Gynecologic Oncology, 1992
• Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure
  The Journal of Steroid Biochemistry and Molecular Biology, 1990
• p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
  Molecular and Cellular Biology, 1989
• Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
  Science, 1987